US2010255507A1PendingUtilityA1

Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma

59
Assignee: US HEALTHPriority: Oct 23, 2000Filed: Oct 10, 2008Published: Oct 7, 2010
Est. expiryOct 23, 2020(expired)· nominal 20-yr term from priority
Inventors:Eric O. LongSumati Rajagopalan
A61K 2039/505G01N 2500/02G01N 2333/70503A61P 37/00C07K 16/2803
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides antibodies and other ligands that specifically bind to KIR2DL4 receptor and stimulate production of interferon gamma. One embodiment is mAb #33 on deposit at ATCC.

Claims

exact text as granted — not AI-modified
1 . A method of inducing production of interferon gamma in a cell that comprises a KIR2DL4 receptor comprising:
 identifying a cell that comprises a KIR2DL4 receptor;   contacting said cell with a ligand that binds to said receptor; and   measuring the production of interferon gamma by said cell.   
     
     
         2 . The method of  claim 1 , wherein said ligand is selected from the group consisting of a monoclonal antibody, mAb #33; a monoclonal antibody, mAb #36; a monoclonal antibody, mAb #64, and HLA-G. 
     
     
         3 . The method of  claim 1 , wherein said ligand is a fragment of monoclonal antibody, mAb #33; a monoclonal antibody, mAb #36; or a monoclonal antibody, mAb #64, that induces production of interferon gamma by said cell. 
     
     
         4 . The method of  claim 1 , wherein said cell is a NK cell. 
     
     
         5 . The method of  claim 1 , wherein said cell is genetically engineered to express said KIR2DL4 receptor. 
     
     
         6 . A method of identifying a compound that induces production of interferon gamma by a cell comprising:
 identifying a cell that comprises a KIR2DL4 receptor;   contacting said cell with a candidate compound; and   measuring the production of interferon gamma by said cell.   
     
     
         7 . The method of  claim 6 , wherein said compound is selected from the group consisting of a monoclonal antibody, mAb #33; a monoclonal antibody, mAb #36; a monoclonal antibody, mAb #64, and HLA-G. 
     
     
         8 . The method of  claim 6 , wherein said compound is a fragment of monoclonal antibody, mAb #33; a monoclonal antibody, mAb #36; or a monoclonal antibody, mAb #64. 
     
     
         9 . The method of  claim 6 , wherein said cell is a NK cell. 
     
     
         10 . The method of  claim 6 , wherein said cell is genetically engineered to express said KIR2DL4 receptor. 
     
     
         11 . A method of identifying a compound that inhibits production of interferon gamma by a cell comprising:
 identifying a cell that comprises a KIR2DL4 receptor;   contacting said cell with a candidate compound that inhibits production of interferon gamma before, during or after contacting said cell with a ligand for said KIR2DL4 receptor that induces production of interferon gamma; and   measuring the production of interferon gamma by said cell.   
     
     
         12 . The method of  claim 11 , wherein said ligand for said KIR2DL4 receptor that induces production of interferon gamma is selected from the group consisting of a monoclonal antibody, mAb #33; a monoclonal antibody, mAb #36; a monoclonal antibody, mAb #64, and HLA-G. 
     
     
         13 . The method of  claim 11 , wherein said ligand for said KIR2DL4 receptor that induces production of interferon gamma is a fragment of monoclonal antibody, mAb #33; a monoclonal antibody, mAb #36; or a monoclonal antibody, mAb #64. 
     
     
         14 . The method of  claim 11 , wherein said cell is a NK cell. 
     
     
         15 . The method of  claim 11 , wherein said cell is genetically engineered to express said KIR2DL4 receptor. 
     
     
         16 . A method of making a therapeutic composition comprising:
 providing the compound that inhibits production of interferon gamma identified by the method of  claim 7 ; and   formulating said compound for administration to a mammal.   
     
     
         17 . The method of  claim 16 , wherein said mammal is a human. 
     
     
         18 . The method of  claim 16 , wherein said therapeutic composition is formulated for intravenous administration. 
     
     
         19 . The method of  claim 16 , wherein said therapeutic composition is formulated for oral administration. 
     
     
         20 . The method of  claim 16 , wherein said therapeutic composition is formulated for intramuscular administration.

Join the waitlist — get patent alerts

Track US2010255507A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.